Global Health Solutions v. Selner: Federal Circuit Affirms Patent Invalidity
Global Health Solutions, LLC appealed a patentability ruling involving two pharmaceutical delivery system patents — an ionic nanovesicle suspension and a petrolatum-based active ingredient platform. The Federal Circuit affirmed the lower decision in full, closing a dispute that ran for 805 days.
Federal Circuit closes nanovesicle patent appeal after 805-day fight
Global Health Solutions, LLC filed appeal No. 23-2009 at the Court of Appeals for the Federal Circuit on 13 June 2023, challenging an invalidity or cancellation determination affecting two pharmaceutical delivery system patents: US20170333346A1 (application no. US15/672197), directed to an ionic nanovesicle suspension and biocide prepared therefrom, and US20180036236A1 (application no. US15/549111), covering petrolatum-based delivery systems for active ingredients. The respondent was Marc Selner, represented by Anthony H. Handal.
The Federal Circuit issued its order on 26 August 2025, affirming the decision below in its entirety. An affirmance at this level means the appellate panel found no reversible legal or factual error in the underlying patentability determination. For Global Health Solutions, the ruling exhausts appellate options at the Federal Circuit level and leaves the patents in the status assigned by the tribunal below. For Marc Selner, the affirmance validates his position throughout the invalidity or cancellation proceeding.
The 805-day duration — from filing to final order — is consistent with a substantive Federal Circuit appeal rather than a procedural dismissal, suggesting the panel engaged with the merits of the patentability arguments. The basis of termination is recorded as ‘Appeal Dismissed,’ which alongside the AFFIRMED order language likely reflects a procedural posture in which the court affirmed the lower ruling and simultaneously terminated the appeal. The precise scope of the invalidity finding — whether claim-by-claim or patent-by-patent — is not determinable from the public record.
Filing to Appeal Dismissed in 805 days
805 days — longer than the median Federal Circuit appeal cycle of roughly 18–24 months
Federal Circuit affirms: what the ruling means for both parties
Affirmance means the lower decision survives intact
When the Federal Circuit issues an AFFIRMED order, it has reviewed the record and found no reversible error — whether legal or factual — in the tribunal’s ruling below. The prior patentability or invalidity determination therefore stands as the operative legal outcome. The appellate court does not re-try the case; it reviews whether the lower body applied the correct legal standards and whether its factual findings were supported by substantial evidence.
No reversible error foundGlobal Health Solutions loses appellate challenge
For Global Health Solutions as appellant, affirmance is an adverse result. The invalidity or cancellation finding against US20170333346A1 and US20180036236A1 is now upheld at the Federal Circuit level. Meaningful further appellate options are limited to a petition for en banc rehearing or a certiorari petition to the Supreme Court — both statistically unlikely to succeed in the absence of a significant circuit split or constitutional question.
Appellate options largely exhaustedSelner’s invalidity position is fully validated on appeal
Marc Selner, as the prevailing respondent, benefits from a now-affirmed invalidity or cancellation ruling on both patents in suit. The Federal Circuit’s stamp of approval raises the bar for any future attempt by Global Health Solutions to re-assert or revive claims in these patents. The ruling also strengthens Selner’s freedom-to-operate position in the nanovesicle and petrolatum delivery system technology space covered by the invalidated claims.
Invalidity ruling confirmedPharmaceutical delivery IP: higher bar after affirmance
An affirmed invalidity finding on nanovesicle suspension and petrolatum-based delivery patents signals that the claimed inventions did not meet patentability thresholds under review. For competitors and R&D teams working in topical or biocide delivery platforms, this outcome suggests that the specific claim architectures asserted here are no longer a blocking risk. However, related continuation or divisional patents — if any exist — would require independent FTO analysis.
Delivery platform claims unenforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Global Health Solutions, LLC | Company | Pharmaceutical IP holder — owner of ionic nanovesicle and petrolatum delivery system patentsSearch in Eureka ↗ |
| Defendant | Marc Selner | Individual | Marc Selner — respondent in invalidity/cancellation action involving drug delivery patentsSearch in Eureka ↗ |
| Plaintiff counsel | Jonathan W.S. England | Attorney | Counsel for Global Health Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Russell T. Wong | Attorney | Counsel for Global Health Solutions, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Blank Rome LLP | Law Firm | Representing Global Health Solutions, LLCSearch in Eureka ↗ |
| Defendant counsel | Anthony H. Handal | Attorney | Counsel for Marc SelnerSearch in Eureka ↗ |
| Defendant law firm | Anthony H. Handal | Law Firm | Representing Marc SelnerSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The order language — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is the Federal Circuit’s standard affirmance formulation, indicating the panel completed merits review and found the patentability or invalidity determination below free of reversible error. The court applies de novo review to questions of law and substantial evidence review to factual findings in patentability proceedings. The concise order language does not reveal whether all claims were addressed uniformly or whether any judge wrote separately; the full opinion, if published, would contain that detail.
US20170333346A1 & US20180036236A1 — Pharmaceutical Delivery Systems
US20170333346A1 (application no. US15/672197) covers an ionic nanovesicle suspension and a biocide prepared therefrom — a formulation-level invention in the topical pharmaceutical and antimicrobial delivery space. US20180036236A1 (application no. US15/549111) covers petrolatum-based delivery systems for active ingredients, a technology relevant to topical drug and cosmetic formulation platforms. Both patents were the subject of an invalidity or cancellation action, with patentability challenged and ultimately denied through to Federal Circuit affirmance.
Nanovesicle-based delivery and petrolatum carrier platforms occupy a commercially active segment of the pharmaceutical formulation market, with applications ranging from topical antimicrobials to dermatological therapeutics. The invalidation of these specific claims — affirmed at the Federal Circuit — removes them as enforcement tools but does not eliminate the broader competitive landscape around similar delivery technologies. Companies holding or developing patents in structurally related nanovesicle or lipid-carrier delivery claims should treat this outcome as a signal to audit claim differentiation strategies.
Should you run an FTO against US20170333346A1 and US20180036236A1?
R&D teams and product counsel working on ionic nanovesicle suspensions, biocide formulations, or petrolatum-based active ingredient delivery platforms should note that the specific claims in these two application numbers have been invalidated and that ruling is now affirmed. However, relying solely on this case for clearance is risky: related family members, continuations, or divisional applications covering overlapping technology may remain active and enforceable.
PatSnap Eureka’s FTO Search Agent can map the full patent family around US15/672197 and US15/549111, identify any co-pending or surviving continuations, and surface third-party patents in the nanovesicle and petrolatum delivery space that may present independent blocking risk. Running a targeted FTO before product launch or licensing negotiation in this technology area is strongly advisable.
Run a freedom-to-operate analysis on US20170333346A1 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in pharmaceutical delivery patent validity
Federal Circuit appeals affirming invalidity of pharmaceutical delivery system patents — including nanovesicle and topical formulation claims — across post-grant and cancellation proceedings.
What this case signals for the pharmaceutical delivery IP landscape
An affirmed invalidity ruling at the Federal Circuit carries significant weight for anyone developing or licensing nanovesicle or petrolatum-based delivery technologies.
Affirmed invalidity at the Federal Circuit clears a path for competitors
With both patents upheld as invalid by the Federal Circuit, companies working in ionic nanovesicle suspension or petrolatum-based active ingredient delivery no longer face the blocking risk of these specific claims. Product teams should still audit the broader portfolio for related applications that may cover similar claim scope.
Prosecution history and claim architecture matter at appellate review
The Federal Circuit’s affirmance suggests the invalidity arguments against these claims were legally and factually robust enough to survive full appellate scrutiny. IP teams building or licensing pharmaceutical delivery patents should ensure claim differentiation is defensible under the patentability standards applied in similar cancellation proceedings.
Global v Marc — key questions answered
The Federal Circuit affirmed the invalidity or cancellation determination against Global Health Solutions’ two patents — US20170333346A1 (ionic nanovesicle suspension) and US20180036236A1 (petrolatum-based delivery systems). The order, issued 26 August 2025, found no reversible error in the lower patentability ruling.
The case involved US20170333346A1 (application US15/672197), covering an ionic nanovesicle suspension and biocide prepared therefrom, and US20180036236A1 (application US15/549111), covering petrolatum-based delivery systems for active ingredients. Both are pharmaceutical formulation and delivery patents.
An AFFIRMED order means the Federal Circuit reviewed the record and found no reversible legal or factual error in the lower tribunal’s invalidity or cancellation ruling. The prior decision stands as the operative outcome. The court applies de novo review to legal questions and substantial evidence review to factual findings in patentability proceedings.
The affirmance is specific to the claims at issue in US20170333346A1 and US20180036236A1. It does not automatically invalidate related family members, continuations, or divisional applications. A full patent family search is required to assess whether related claims remain active and enforceable.
The appeal ran 805 days from filing on 13 June 2023 to closure on 26 August 2025. This duration is consistent with a substantive Federal Circuit appeal on the merits and longer than many procedurally resolved appeals, suggesting meaningful engagement with the patentability arguments by the panel.
PatSnap Eureka searches patents and litigation data to answer instantly.